Last reviewed · How we verify

NCT04048655

Reversal of Neuromuscular Blockade During the General Anaesthesia

Active, enrolled NA Last updated 16 September 2025
What this trial tests

NA trial testing Neostigmine, Combinations in Neuromuscular Blockade in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 April 2020
Primary endpoint
1 September 2025
31 December 2025

Quick facts

Lead sponsorTampere University Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment120
Start date8 April 2020
Primary completion1 September 2025
Estimated completion31 December 2025
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Tampere University Hospital

Who can join

Adults 18 to 65, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are individual reports indicating that after the reversal of nondepolarizing neuromuscular blockade with neostigmine, some patients starts to relax spontaneously again after the tof ratio has already recovered to the safe level (\>90%). The mechanism behind this in not well understood, and the incidence of the phenomenon is unclear. In this study the investigators try to determine the incidence of the aforementioned postrecovery relaxation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuromuscular Blockade

Currently open trials in the same condition.

Other Tampere University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04048655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing